CD44v5 antibody | VFF-8
CD44 isoforms containing one or more sequences encoded by the variant region exons have a much more restricted expression pattern both in terms of organ specificity and immune activation (Mackay et al. 1994). CD44 isoforms bearing the v5 exon product have been implicated in various neoplasms including breast cancer (Tempfer et al. 1996), renal cell carcinoma (Wu et al. 2003) and cervical cancer metastases (Kainz et al. 1996).
Mouse anti Human CD44v5 antibody has proved a useful reagent for the imunohistochemical or flow cytometric evaluation of CD44 variants containing the v5exon product expression in normal and neoplasic cells (Ringel et al. 2001)
- Target Species
- Product Form
- Purified IgG - liquid
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- P16070 Related reagents
- Entrez Gene
- CD44 Related reagents
- For research purposes only
Applications of CD44v5 antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen||1/10|
|Immunohistology - Paraffin 1||1/10|
- 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Secondary Antibodies Available
Negative Isotype Controls Available
|Description||Product Code||Applications||Pack Size||List Price||Quantity|
|Mouse IgG1 Negative Control||MCA928||F||100 Tests|
Product Specific References
References for CD44v5 antibody
Bànkfalvi, A. et al. (1998) Gains and losses of CD44 expression during breast carcinogenesis and tumour progression.
Histopathology. 33 (2): 107-16.
Alam, T.N. et al. (2004) Differential expression of CD44 during human prostate epithelial cell differentiation.
J Histochem Cytochem. 52: 1083-90.
Rajarajan, A. et al. (2012) CD44 expression in oro-pharyngeal carcinoma tissues and cell lines.
PLoS One. 7: e28776.
Hanley, W.D. et al. (2006) Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells.
FASEB J. 20: 337-9.
Chaiyarit, P. et al. (2008) Alteration of the expression of CD44 [corrected] isoforms in oral epithelia and saliva from patients with oral lichen planus.
J Clin Immunol. 28: 26-34.
Shirure, V.S. et al. (2015) CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions.
Am J Physiol Cell Physiol. 308 (1): C68-78.
Spadea, A. et al. (2019) Evaluating the Efficiency of Hyaluronic Acid for Tumor Targeting via CD44.
Mol Pharm. 16 (6): 2481-93.